RecruitingPhase 1NCT04861051
Understanding Ketamine's Dissociative Effects (KD Study)
Understanding Ketamine's Dissociative Effects in Epilepsy (KD Study)
Sponsor
Stanford University
Enrollment
20 participants
Start Date
Jul 26, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to understand how ketamine brings about dissociative symptoms.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Ketamine for people with epilepsy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGKetamine
Study participants will receive 0.5mg/kg of ketamine - one single infusion
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04861051
Related Trials
Tumor Related Epilepsy
NCT026393251 location
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy
NCT025318801 location
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
NCT021079891 location
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT075638813 locations
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients
NCT0705162910 locations